Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II
Hematology Disease Topics & Pathways:
therapy sequence, Biological, multiple myeloma, Diseases, Combinations, Therapies, immunotherapy, Plasma Cell Disorders, Lymphoid Malignancies
Methods: The Flatiron Health Database was used, comprising de-identified EHR-derived data for patients treated in the Flatiron Health network. Patients were excluded if they had no record of a 1L treatment recognized as an induction regimen based on NCCN guidelines, a 1L regimen that contained an active therapy for another cancer type, 1L initiated >60 days after MM diagnosis, and <3 consecutive months of data. Treatments were classified into 15 mutually exclusive categories (inclusive of steroids): Chemotherapy, IMiD, IMiD+chemo, PI, PI+chemo, IMiD+PI, IMiD+PI+chemo, aCD38, aCD38+chemo, aCD38+IMiD, aCD38+IMiD+chemo, aCD38+PI, aCD38+PI+chemo, aCD38+IMiD+PI, and Other. Treatment use and sequencing patterns were assessed using proportions.
Results: 5890 adult patients diagnosed with MM between 1/1/2011 and 12/31/19 were included. 45% of patients were female, 60% were white, and the median age was 69 (IQR = 61-76). Nearly 90% of the cohort were from community practices. Across years and lines, the most common treatment categories were IMiD, PI, and IMiD+PI. After 2015, IMiD+ PI was the dominant category in 1-3L and IMiD was the dominant category in 4L+. After 2015 and across lines, the most common aCD38 containing treatment was aCD38+IMiD. After 2015, aCD38 treatments were used in 2-4% of 1L patients regardless of subgroup. Between 2015 and 2019, the use of aCD38 treatments in 2L increased from 1% to 20% in all, standard risk, SCT eligible, and community patients, 2% to 15% in SCT ineligible, and 10% to 20% academic patients. Between 2015 to 2019, the use of aCD38 treatments in 3L increased from 10% to >30% in all, standard risk and SCT eligible patients, 10% to 20% in academic patients, and 2% to 20% in community and SCT ineligible patients. Over 40% of 4L+ patients were treated with aCD38 treatments by 2019 regardless of subgroup. As shown in Figure 1, of the patients receiving an IMiD, PI, or IMiD+PI in 1-3L in 2015-2019, 10-25% stayed with the same treatment category (though likely switched drugs within the class), whereas 25-50% switched to a different treatment category, in the next line. These proportions generally hold regardless of subgroup. Of the patients receiving an aCD38 regimen in 1-2L in 2015-2019, 10-20% stayed with the same treatment category, 5-40% switched to a different treatment category, and 5-25% stayed with an aCD38 regimen but switched to a different combination in the next line. Of 3L patients receiving an aCD38 regimen, under 15% stayed with the same treatment category, 5-40% switched to a different treatment category, and 1-40% stayed with an aCD38 regimen but switched to a different combination in 4L.
Conclusions: Our findings suggest that across lines, IMiD, PI, and IMiD+PI are the most common treatment categories but that aCD38 treatments are increasingly used in recent years and in later lines. For the major treatment categories (IMiD, PI, IMiD+PI), <25% patients will remain with the same treatment category, whereas 25-50% will switch to another treatment category, in the next line. For aCD38 treatments, 20% or less will remain with the same treatment category, whereas 5-40% will switch, in the next line.
Disclosures: Gershon: Genentech, Inc./ F. Hoffmann-La Roche: Current Employment, Current equity holder in publicly-traded company. Liu: Genesis Research receives consulting fees from Genentech, Inc. a member of the F. Hoffmann-La Roche Group: Consultancy; Genesis Research: Current Employment. James: Genentech, Inc./ F. Hoffmann-La Roche: Current Employment, Current equity holder in publicly-traded company. Williamson: Amgen: Current equity holder in publicly-traded company; F. Hoffmann-La Roche: Current Employment, Current equity holder in publicly-traded company. Hong: Genentech, Inc.: Current Employment; F. Hoffmann-La Roche: Current equity holder in publicly-traded company. Sarsour: F. Hoffmann-La Roche: Current equity holder in publicly-traded company; Genentech, Inc.: Current Employment.
See more of: Oral and Poster Abstracts